In accordance with a decision by the Board of Directors, Orion Corporation has on 12 March 2012 transferred altogether 87,763 Orion Corporation B-shares held by the company as a share reward for 2011 to the persons employed by the Orion Group and belonging to the Share-based Incentive Plan of the Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 24 March 2010. The price per share of the transferred shares is EUR 16.3848, which is the volume weighted average quotation of the Orion Corporation B-share on 12 March 2012. Accordingly, the total transaction price of the transferred shares is EUR 1,437,979.20.
After the share transfer, the total number of own B-shares held by Orion Corporation is 325,991.
Orion Corporation has informed about the Share-based Incentive Plan in a stock exchange release on 18 February 2010.
|Timo Lappalainen |
President and CEO
SVP, Corporate Functions
Orionintie 1A, 02200 Espoo
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2011 amounted to EUR 918 million. The Company invested EUR 88 million in research and development. At the end of 2011, the Group had about 3,400 employees, of whom about 2,700 worked in Finland and the rest in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.